Clinical study to evaluate the efficacy and safety of a unani formulation in Kalaf (Melasma).

A Randomized, Parallel Group, Open Label, Active Controlled Clinical Study to evaluate the Efficacy and Safety of a topical Herbomineral Unani Formulation in the Management of Kalaf (Melasma).

Status

Active, not recruiting

Phases

Phase 2Phase 3

Study type

Interventional

Source

CTRI

Registry ID

CTRI/2023/03/050201

Enrollment

Registered

2023-03-01

Start date

Unknown

Completion date

Unknown

Last updated

2023-03-06

For informational purposes only — not medical advice. Sourced from public registries and may not reflect the latest updates. Terms

Conditions

Health Condition 1: L811- Chloasma

Interventions

Intervention1: Herbomineral Unani Formulation: Dosage Form: Tila (Liniment) Dose: Quantity Sufficient Mode of Administration: Local Application. Composition: 1. Turmus(Lupinus albus Linn) 2. Tukhme

Eligibility

Inclusion criteria

Inclusion criteria: Participant having single or multiple, irregular or regular, light to dark brown macules on the face (cheeks, nose, forehead, upper lip and chin). Chronicity of disease should be more than 4 months.

Exclusion criteria

Exclusion criteria: women who are pregnant and lactating. Participant aged less than 18 years and more than 55 years. Significant cardiovascular / pulmonary / hepato-renal dysfunction. Known case of diabetes mellitus, HIV / AIDS and malignancy. Those unwilling to come for regular follow-up for the entire duration of the study.

Design outcomes

Primary

Measure	Time frame
27% reduction in MASI score from baseline after 8 weeks of treatment.Timepoint: 8 weeks	—

Secondary

Measure	Time frame
Systemic safety assessmentTimepoint: 8 weeks	—

Countries

India

Contacts

Public ContactDr Sheikh Ayesha Aijaz

National Research Institute of Unani Medicine for Skin Disorders.

ccrumnawab@gmail.com08100992044

Outcome results

None listed

Source: CTRI (via WHO ICTRP) · Data processed: Feb 4, 2026